login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
ELEDON PHARMACEUTICALS INC (ELDN) Stock News
USA
- NASDAQ:ELDN -
US28617K1016
-
Common Stock
2.44
USD
-0.11 (-4.31%)
Last: 9/24/2025, 12:19:54 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ELDN Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
a month ago - By: The Motley Fool
Eledon Posts Narrower Loss in Q2
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
2 months ago - By: Benzinga
- Mentions:
USPH
EBS
HAE
CCCC
...
12 Health Care Stocks Moving In Thursday's Intraday Session
2 months ago - By: Benzinga
- Mentions:
EXAS
TNDM
IRWD
OM
...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
2 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
2 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
2 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025
2 months ago - By: Eledon Pharmaceuticals, Inc.
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
2 months ago - By: Eledon Pharmaceuticals, Inc.
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
3 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
3 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
4 months ago - By: Zacks Investment Research
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock
4 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
4 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
6 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
6 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
7 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
7 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
8 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
8 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
8 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
8 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
8 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
8 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
11 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
11 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
a year ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
a year ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
a year ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
a year ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
a year ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
a year ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
a year ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Please enable JavaScript to continue using this application.